Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Oramed Pharmaceuticals (ORMP) EPS (Weighted Average and Diluted) (2022 - 2025)

Oramed Pharmaceuticals' EPS (Weighted Average and Diluted) history spans 4 years, with the latest figure at $1.72 for Q4 2025.

  • For Q4 2025, EPS (Weighted Average and Diluted) changed N/A year-over-year to $1.72; the TTM value through Dec 2025 reached $2.97, changed N/A, while the annual FY2025 figure was $1.5, 412.5% up from the prior year.
  • EPS (Weighted Average and Diluted) reached $1.72 in Q4 2025 per ORMP's latest filing, up from $1.13 in the prior quarter.
  • In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $1.72 in Q4 2025 to a low of -$0.48 in Q3 2024.
  • Average EPS (Weighted Average and Diluted) over 4 years is $0.12, with a median of -$0.08 recorded in 2023.
  • Peak YoY movement for EPS (Weighted Average and Diluted): surged 833.33% in 2024, then crashed 575.0% in 2025.
  • A 4-year view of EPS (Weighted Average and Diluted) shows it stood at -$0.3 in 2022, then surged by 210.3% to $0.33 in 2023, then crashed by 245.45% to -$0.48 in 2024, then surged by 458.33% to $1.72 in 2025.
  • Per Business Quant, the three most recent readings for ORMP's EPS (Weighted Average and Diluted) are $1.72 (Q4 2025), $1.13 (Q3 2025), and $0.31 (Q2 2025).